Median overall survival for patients with newly diagnosed multiple myeloma may surpass ten years. Nonetheless, many patients face considerable treatment-related morbidity and relapsed disease. Owing to this typically long overall survival, most multiple myeloma trials now use progression-free survival as their primary end point. In this Comment, we highlight circumstances in which this end point does not best answer the questions that various trials seek to investigate.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
Clinical Hematology International Open Access 03 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
31 May 2023
In the version of this article initially published, the given name and surname for Ghulam Rehman Mohyuddin were presented incorrectly and are now amended in the online version of the article.
References
Mohyuddin, G. R. et al. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. Am. J. Hematol. 96, 690–697 (2021).
Haslam, A. & Prasad, V. When is crossover desirable in cancer drug trials and when is it problematic? Ann. Oncol. 29, 1079–1081 (2018).
Schjesvold, F. H. et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 9, e98–e110 (2022).
Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 21, 1630–1642 (2020).
Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29–37 (2010).
Gill, S. K. et al. Inferior outcomes of patients with quad and penta-refractory multiple myeloma (mm) compared to those of patients who have been quad and penta exposed. Blood 138, 4742–4742 (2021).
Gyawali, B. & Prasad, V. Combining drugs and extending treatment — a PFS end point is not sufficient. Nat. Rev. Clin. Oncol. 14, 521–522 (2017).
Mohyuddin, G. R., Koehn, K., Abdallah, A. O., Goodman, A. M. & Prasad, V. Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review. JAMA Netw. Open 4, e218084 (2021).
Munshi, N. C. et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 3, 28–35 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Cliff, E.R.S., Mohyuddin, G.R. Overall survival as a primary end point in multiple myeloma trials. Nat Rev Clin Oncol 19, 565–566 (2022). https://doi.org/10.1038/s41571-022-00665-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00665-7
This article is cited by
-
The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
Clinical Hematology International (2023)